Outset Medical, INC 8-K filings

Outset Medical announced its second quarter 2026 financial results, reporting a slight 1% year-over-year revenue increase to $31.6 million, alongside a significant expansion in gross margin to 42% and a new three-year, $40 million agreement with HCA Healthcare.

Outset Medical, Inc. announced the departure of Executive Vice President Marc Nash, effective June 5, 2026.

Outset Medical, Inc. reported improved financial results for Q4 and full year 2025, driven by significant gross margin expansion and reduced operating expenses, alongside positive 2026 guidance.

Outset Medical, Inc. announced FDA 510(k) clearance for its next-generation Tablo platform, featuring enhanced cybersecurity and reliability, with shipping expected in Q2 2026.

Outset Medical, Inc. announced its unaudited fourth quarter and full-year 2025 revenue, alongside the appointment of Karen N. Prange to its Board of Directors.

Outset Medical reported third-quarter results, revising its 2025 revenue guidance downwards due to shifted timing for large customer opportunities.

Outset Medical reported robust second-quarter 2025 financial results, marked by significant revenue growth, improved gross margins, and reduced operating expenses, leading to raised full-year revenue guidance.

Outset Medical, Inc. announced the appointment of Renee Gaeta as its new Chief Financial Officer, effective June 3, 2025, while also reiterating its 2025 financial guidance and detailing the outcomes of its Annual Meeting of Stockholders.

Outset Medical announces the appointment of Kevin OBoyle to its Board of Directors and Audit Committee Chair, succeeding Dale E. Jones, effective May 14, 2025.

Outset Medical's first quarter 2025 results show a 6% revenue increase and significant progress in gross margin expansion and cash use reduction.

Outset Medical enacted a one-for-fifteen reverse stock split of its common stock, effective March 20, 2025, to increase its stock price.

Outset Medical has announced a one-for-fifteen reverse stock split of its common stock, effective March 20, 2025, to increase its stock price and improve its standing on the Nasdaq.

Outset Medical corrected a mathematical error in the Certificate of Designation for its Series A Non-Voting Convertible Preferred Stock and subsequently issued and converted a significant number of these shares into common stock.

Outset Medical's stockholders approved proposals including the issuance of stock, a potential reverse stock split, and adjournment options at a Special Meeting held on March 5, 2025.

Outset Medical receives a second Nasdaq delisting notice for failing to maintain the minimum bid price, while also reporting full year 2024 results and securing new financing.

Outset Medical's Q4 and full-year 2024 results exceeded prior guidance, with significant improvements in gross margin and recurring revenue growth.

Outset Medical has amended its bylaws to change the voting requirements for matters other than director elections to a majority of votes cast, rather than a majority of voting power present.

Outset Medical finalized a $100 million loan, issued warrants for common stock, and completed a private placement of Series A preferred stock, restructuring its debt and equity.

Outset Medical has secured $169 million in a private placement and up to $125 million in debt financing to support its operations and retire existing debt.

Outset Medical announced its third quarter 2024 financial results, showing sequential revenue growth and improved gross margins, while also updating its full-year revenue and non-GAAP gross margin guidance.

Outset Medical has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing its listing at risk.

Outset Medical announces the resignation of board member Jim Hinrichs due to a conflict of interest arising from a Baxter International spinoff, leading to changes in committee leadership.

Outset Medical's Q2 2024 results show increased gross margins and recurring revenue, but a decline in product revenue and lowered full-year revenue guidance.

Outset Medical's annual meeting saw the election of three Class I directors, approval of executive compensation, and ratification of KPMG as the independent auditor.

Outset Medical's first quarter results show revenue decline but improved gross margins and cost-cutting measures, alongside a workforce reduction.

Outset Medical has received FDA 510(k) clearance for its TabloCart with prefiltration, allowing the company to resume distribution of the product in the United States.

Outset Medical has appointed Brent D. Lang to its board of directors, filling a vacancy created by the resignation of Catherine Szyman.

Outset Medical reported a 13% increase in full-year revenue for 2023, alongside a significant improvement in gross margins, but a decrease in fourth-quarter revenue compared to the previous year.